Tykerb Weekly Feed
32 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by H4B Catapult
Scoop.it!

No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer

No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer | Tykerb Weekly Feed | Scoop.it
Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

The ASCO Post

The ASCO Post | Tykerb Weekly Feed | Scoop.it
Similar High Complete Response Rate w/Neoadjuvant Trastuzumab, Lapatinib, and Combo Rx in HER2+ Breast Cancer http://t.co/VS4D1ENRVL #bcsm
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

5-FU Strikes Out in Early-Stage Breast Ca - MedPage Today

5-FU Strikes Out in Early-Stage Breast Ca - MedPage Today | Tykerb Weekly Feed | Scoop.it
5-FU Strikes Out in Early-Stage Breast Ca MedPage Today The drug has been used for decades in other cancers and in other forms of breast cancer, but it has not been clear if it added anything as adjuvant treatment, combined with an anthracycline,...
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Study Identifies Highly Effective Treatment Option for Patients With ...

Study Identifies Highly Effective Treatment Option for Patients With ... | Tykerb Weekly Feed | Scoop.it
... treatments used before the development of trastuzumab. In HER2-positive breast cancers, anthracyclines improved outcomes dramatically while adding little or no incremental benefit to the other subtypes that represent 75 to 80 percent of t.
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Adjuvant Trastuzumab plus Docetaxel/Carboplatin 'Ideal' for HER2-positive Breast Cancer - Chemotherapy Advisor

Adjuvant Trastuzumab plus Docetaxel/Carboplatin 'Ideal' for HER2-positive Breast Cancer - Chemotherapy Advisor | Tykerb Weekly Feed | Scoop.it
HER2-positive breast cancer patients benefit from adding trastuzumab to docetaxel/carboplatin.
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

PIK3CA Mutations Linked to Treatment Resistance in HER2+, HR+ Breast Cancer - OncLive

PIK3CA Mutations Linked to Treatment Resistance in HER2+, HR+ Breast Cancer - OncLive | Tykerb Weekly Feed | Scoop.it
OncLive PIK3CA Mutations Linked to Treatment Resistance in HER2+, HR+ Breast Cancer OncLive These findings, reported at the 2013 San Antonio Breast Cancer Symposium, stemmed from an analysis of patients in the GeparQuinto and GeparSixto trials, who...
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

As Herceptin Goes Off Patent, 'Biosimilars' Emerge - Medscape

As Herceptin Goes Off Patent, 'Biosimilars' Emerge Medscape SAN ANTONIO — As the epoch-making breast cancer targeted therapy trastuzumab (Herceptin, Genentech) is coming to the end of its patent protection, a new kind of knock-off product is being...
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Ventana announces HER2 companion diagnostic | Arizona ...

Ventana announces HER2 companion diagnostic | Arizona ... | Tykerb Weekly Feed | Scoop.it
Ventana announces HER2 companion diagnostic to identify breast cancer patients for Roche's latest targeted medicines, Perjeta and Kadcyla. VENTANA HER2 (4B5) IHC assay label expansion coincides with therapy ...
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

The ASCO Post

The ASCO Post | Tykerb Weekly Feed | Scoop.it
8-Gene Profile Predicts Benefit of Adjuvant Trastuzumab in HER2-Negative Disease - @ASCOPost http://t.co/INHme0XH1C #bcsm #dox
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Pathologic complete response after preoperative anti-HER2 therapy correlates ... - 7thSpace Interactive (press release)

Pathologic complete response after preoperative anti-HER2 therapy correlates ...
H4B Catapult's insight:

"Conclusion: In this exploratory study, pCR with preoperative anti-HER2 therapy and chemotherapy correlated with the levels and phosphorylation status of specific baseline signal pathway proteins in tumor cells.

These data may provide candidate biomarkers to stratify initial treatment and potential combination therapies for future study. Tissue preservation technology introduced here makes this procedure widely feasible.Trial registration: ClinicalTrials.gov: NCT00524303"

more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

STAT3 activation in HER2-overexpressing breast c... [Int J Oncol. 2013] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
H4B Catapult's insight:

Interesting conclusion, "Based on our findings, targeting pSTAT3 could overcome Herceptin-induced resistance in HER2-overexpressing breast tumors."

more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Heregulin Induces Resistance to Lapatinib-mediate... [Cancer Sci. 2013] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Analysis of Circulating Tumore DNA to Monitor Metestatic Breast Cancer

H4B Catapult's insight:

For the medics or scientifically inclined ... Possible future alternative to standard biopsies.

more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Grey Horizon: Combined therapy linked to lower chance of recurrence in women with small, HER2-positive breast cancers

Grey Horizon: Combined therapy linked to lower chance of recurrence in women with small, HER2-positive breast cancers | Tykerb Weekly Feed | Scoop.it
Combined therapy linked to lower chance of recurrence in women with small, HER2-positive breast cancers: In a ... http://t.co/J5Jd5QQsrm
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients

According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients | Tykerb Weekly Feed | Scoop.it
From BioPortfolio:  BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that,... (According to Surveyed U.S.
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Studies Point to Challenges of HER2 Resistance

Studies Point to Challenges of HER2 Resistance | Tykerb Weekly Feed | Scoop.it
SAN ANTONIO -- A common mutation in HER2-positive breast cancer reduced the odds of pathologic complete response to neoadjuvant therapy by 50%, an analysis of two large clinical trials showed.
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

These Three Companies Are Paving The Way To Breast Cancer Treatment - Forbes

These Three Companies Are Paving The Way To Breast Cancer Treatment - Forbes | Tykerb Weekly Feed | Scoop.it
These Three Companies Are Paving The Way To Breast Cancer Treatment Forbes Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment surgery with or without radiation therapy with the goal of...
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Surgery Unnecessary for Metastatic Breast Cancer Patients? | Cancer Network

Surgery Unnecessary for Metastatic Breast Cancer Patients? | Cancer Network | Tykerb Weekly Feed | Scoop.it
Surgical removal of primary breast cancer tumors had no benefit on overall survival in women who presented with metastatic breast cancer, according to the results of a study presented at SABCS.
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Researchers to Present Event-free and Overall Survival Results ...

Researchers to Present Event-free and Overall Survival Results ... | Tykerb Weekly Feed | Scoop.it
Neoadjuvant therapy is treatment given to shrink or eliminate a tumor before surgery. In some patients with breast cancer, neoadjuvant therapy effectively eliminates the tumor, and no invasive cancer is detectable in breast ...
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Ceratin Gene Mutations Make Breast Cancers Treatment-Resistant - Science Daily (press release)

Ceratin Gene Mutations Make Breast Cancers Treatment-Resistant - Science Daily (press release) | Tykerb Weekly Feed | Scoop.it
New York Daily News
Ceratin Gene Mutations Make Breast Cancers Treatment-Resistant
Science Daily (press release)
Dec.
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Cancer Care Ontario Adds PERJETA®-HERCEPTIN® Combo Pack for ... - DigitalJournal.com

Cancer Care Ontario Adds PERJETA®-HERCEPTIN® Combo Pack for ... - DigitalJournal.com | Tykerb Weekly Feed | Scoop.it
Cancer Care Ontario Adds PERJETA®-HERCEPTIN® Combo Pack for ...
DigitalJournal.com
MISSISSAUGA, ON, Dec.
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Nontoxic hydrogel for breast cancer treatment - Medical Xpress

Nontoxic hydrogel for breast cancer treatment - Medical Xpress | Tykerb Weekly Feed | Scoop.it
Nontoxic hydrogel for breast cancer treatment Medical Xpress One such drug is Herceptin, also known as trastuzumab, a monoclonal antibody that can slow or even halt tumor growth in patients with human epidermal growth factor receptor 2...
H4B Catapult's insight:

Although early, this is a new delivery system for Herceptin which may decrease the number of office visits for the patient. Important to watch as it may offer utility for other mAB's will effect how the VDB is delievered. 

more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Mylan Nabs India, Roche Takes Europe in Breast Cancer Therapies - DailyFinance

Mylan Nabs India, Roche Takes Europe in Breast Cancer Therapies - DailyFinance | Tykerb Weekly Feed | Scoop.it
While Roche may have lost the patent battle on its HER2 therapy Herceptin in India, it won a new HER2 therapy approval for Kadycla in
H4B Catapult's insight:

Interesting information on competitive movement regarding generics ROW.

more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials | Tykerb Weekly Feed | Scoop.it
RT @TripCancer: Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer http://t.co/zoLm7DEfnR
more...
No comment yet.
Scooped by H4B Catapult
Scoop.it!

Preferences for oral versus intravenous adjuvant chemotherapy among ea

Preferences for oral versus intravenous adjuvant chemotherapy among ea | Tykerb Weekly Feed | Scoop.it
Peer reviewed article authored by (Ishitobi M, Shibuya K, Komoike Y, Koyama H, Inaji H). Read article or submit your manuscript for publishing.
more...
No comment yet.